NCT03831932 - Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

June 12, 2024

Study Completion Date

March 14, 2026

Conditions

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Elastography

Undergo MRI

DRUG

Osimertinib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Telaglenastat Hydrochloride

Given PO

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

Trial Locations (11)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

22908

University of Virginia Cancer Center, Charlottesville

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33324

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

35233

University of Alabama at Birmingham Cancer Center, Birmingham

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH